This article has been updated to include comments from WaferGen's conference call following the release of results.


NEW YORK (GenomeWeb) - WaferGen Biosystems reported after the close of the market Wednesday that its second quarter revenues fell 6 percent due to reduced SmartChip capital equipment sales.

For the three months ended June 30, the genetic analysis products maker reported total revenues of $1.6 million, compared to $1.7 million in Q2 2014 and short of the consensus analysts' estimate of $2.1 million.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

CNN reports that researchers have tied a new variant to opioid addiction risk.

Organoids derived from patients' tumors may help determine what chemotherapy treatment patients would benefit from, according to New Scientist.

An initiative from GenomeAsia 100K hopes to increase the number of South Asians in genetic research, according to NBC News.

In Science this week: genomic analysis of ancient and modern horses indicates population turnover, and more.